Floatz logo

Larotrectinib

Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion

BayerSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion cohort.

Asset / SponsorPhaseRating
Larotrectinib
Children's Oncology Group
Phase 2CCC
Selpercatinib
Eli Lilly and Company
Phase 1/2CCC
bay2757556
Bayer
D

Same molecule, other indications

Larotrectinib is also rated in:

NTRK fusion positive cancerDormant
BB
Indicative ·
65 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
Locally Advanced Malignant Solid NeoplasmDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →